Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, announced that its CEO, Waqaas Al-Siddiq, was recently interviewed on Newsmax to discuss Remote Patient Monitoring, Telemedicine and how Biotricity and its Bioflux solution is currently being used to remotely monitor patients. “It is exciting and humbling to have the Company and our technology recognized as a leader. Remote Diagnost
REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced that its CEO, Waqaas Al-Siddiq, was recently interviewed on Newsmax to discuss Remote Patient Monitoring, Telemedicine and how Biotricity and its Bioflux solution is currently being used to remotely monitor patients.
“It is exciting and humbling to have the Company and our technology recognized as a leader. Remote Diagnostics, Remote Patient Monitoring and Telemedicine are key components of the future healthcare landscape. Recent events have put a spotlight on the benefits of these technologies and their effectiveness in delivering care. With every solution there are limitations but both Remote Patient Monitoring and Telemedicine can help deliver care, reduce costs, and create benefits for all those involved,” said Dr. Al-Sddiq.
Remote Diagnostics, Remote Monitoring and Telehealth are technologies that will help improve care delivery and reduce costs. The use of these technologies has been growing aggressively but recent events have put them front and center, accelerating this growth. Adoption of these technologies will only grow faster in the coming months and years as the focus continues towards faster care and cost reduction while maintain or improving the quality of care.
To watch the interview please visit:
Newsmax: https://www.youtube.com/watch?v=PhDbJCR3QL0&t=72s
To learn more, join our newsletter at: https://www.biotricity.com/contact-us/ or follow on:
Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
